Locust Street, St. Louis, Missouri 63102-2034:

1. Walden Financial Group, Inc., Pocahontas, Arkansas; to engage *de novo* in the activity of extending credit, pursuant to § 225.28(b)(1) of Regulation Y.

Board of Governors of the Federal Reserve System, November 18, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99–30565 Filed 11–23–99; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11:00 a.m., Monday, November 29, 1999.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: November 19, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99–30699 Filed 11–19–99; 4:43 pm]

BILLING CODE 6210–01–P

GENERAL SERVICES ADMINISTRATION

Interagency Committee for Medical Records (ICMR); Revision of SF 525, Medical Record Radiation Therapy Summary

AGENCY: General Services Administration.

ACTION: Notice.

SUMMARY: The General Services Administration/ICMR is revising the SF 525, Medical Record Radiation Therapy Summary to:

1. Collection information on the sponsor of the patient;

2. Delete ''grade; SSN; rank;'' from ''PATIENT'S IDENTIFICATION'' item and replace with ''ID no. (SSN or other)'';

3. Add standard information fields; and

4. Make the form authorized for local reproduction.

You can obtain the updated form in two ways:

On the internet. Address: http://www.gsa.gov/forms/forms.htm, or;

From Forms-X, Attn.: Barbara Williams, (202) 501–0581.

FOR FURTHER INFORMATION CONTACT: Ms. Barbara Williams, General Services Administration, (202) 501–0581.

DATES: Effective November 24, 1999.

Dated: November 15, 1999.

Barbara M. Williams,

Deputy Standard and Optional Forms Management Officer.

[FR Doc. 99–30599 Filed 11–23–99; 8:45 am]

BILLING CODE 6820–34–M

GENERAL SERVICES ADMINISTRATION

Interagency Committee for Medical Records (ICMR); Automation of Medical Standard Form 525

AGENCY: General Services Administration.

ACTION: Guideline on automating medical standard forms.

BACKGROUND: The Interagency Committee on Medical Records (ICMR) is aware of numerous activities using computer-generated medical forms, many of which are not mirror-like images of the genuine paper Standard/Optional Form. With GSA's approval the ICMR eliminated the requirement that every electronic version of a medical Standard/Optional form be reviewed and granted an exception. The committee proposes to set required fields standards and that activities developing computer-generated versions adhere to the required fields but not necessarily to the image. The ICMR plans to review medical Standard/Optional forms which are commonly used and/or commonly computer-generated. We will identify those fields which are required, those (if any) which are optional, and the required format (if necessary). Activities may not add data elements that would change the meaning of the form. This would require written approval from the ICMR. Using the process by which overprints are approved for paper Standard/Optional forms, activities may add other data entry elements to those required by the committee. With this decision, activities at the local or headquarters level should be able to develop electronic versions which meet the committee's requirements. This guideline controls the ''image'' or required fields but not the actual data entered into the field.

SUMMARY: With GSA's approval, the Interagency Committee on Medical Records (ICMR) eliminated the requirement that every electronic version of a medical Standard/Optional form be reviewed and granted an exception. The following fields must appear on the electronic version of the following form:

ELECTRONIC ELEMENTS FOR SF 525

Item	Placement*
TEXT:	
Title: Radiation Therapy Summary	Bottom right corner of form.
Form ID: Standard Form 525 (Rev. 5–99)	Bottom right corner of form.
Full Figure front and back	
Head—profile—left and right	
DATA ENTRY FIELDS:	
Diagnosis	

ELECTRONIC ELEMENTS FOR SF 525—Continued

Item	Placement*
Sex	
Age	
Date of Consultation	
Narrative Summary—INSTRUCTIONS:	
Include (1) Site of primary and histopathology, (2) Clinical state or class (or exact area if treated for metastasis only), (3) Brief history, (4) Pertinent lab or X-ray findings, (5) Physical findings, (6) Plan of treatment, (7) Dates start and end, (8) Tumor does summary (include special techniques or precautions), (9) Status of tumor at completion of therapy, (10) Tollerance (include medications), (11) Disposition.	
Signature of Physician	
Date (of Signature)	
Relationship to Sponsor	
Sponsor's Name—Last	
Sponsor's Name—First	
Sponsor's Name—MI	
Sponsor's ID Number (SSN or Other)	
Depart./Service	
Organization	
Hospital or Medical Facility	
Records Maintained At	
Patient's Identification	Lower left corner of former.
(Name—last, first, middle; ID No. or SSN; Sex; Date of Birth; Rank/Grade	Lower Left corner of form
Register No.	Lower Left corner of form.
Ward No.	Lower Left corner of form.
Unit Parameters—Field (Allow at least 6 entries)	
Unit Parameters—Unit (Allow at least 6 entries)	
Unit Parameters—Nomenclature (Allow at least 6 entries)	
Unit Parameters—Beam Energy (Allow at least 6 entries)	
Unit Parameters—Calibration Factors (Allow at least 6 entries)	
Unit Parameters—Other Applicable Factors (Allow at least 6 entries)	
Treatment Factors—Field Name (Allow at least 4 entries)	
Treatment Factors—Field Size (Allow at least 4 entries)	
Treatment Factors—SSD/TSD (Allow at least 4 entries)	
Treatment Factors—Angel/ARC (Allow at least 4 entries)	
Treatment Factors—Given Dose (Allow at least 4 entries)	
Time Dose—Point Name (Allow at least 4 entries)	
Time Dose—Dose (Allow at least 4 entries)	
Time Dose—Franctions (Allow at least 4 entries)	
Time Dose—Days (Allow at least 4 entries)	
Time Dose—Inclusive Dates (Allow at least 4 entries)	

*If no placement indicated, items can appear anywhere on the form.

FOR FURTHER INFORMATION CONTACT: CDR Steven S. Kerrick, USN National Naval Medical Center, Department of Ophthalmology, Bethesda, MD 20889–5000 or E-Mail at StevenK966@aol.com.

Dated: November 15, 1999.

Steven S. Kerrick,

Chairperson, Interagency Committee on Medical Records.

[FR Doc. 99–30600 Filed 11–23–99; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99D–4718]

Guidance for Industry on In Vivo Drug Metabolism/Drug Interaction Studies—Study Design, Data Analysis, and Recommendations for Dosing and Labeling; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ''In Vivo Drug Metabolism/Drug Interaction Studies—Study Design, Data Analysis, and Recommendations for Dosing and Labeling.'' This guidance provides recommendations to sponsors of new drug applications (NDA's) and biologics license applications (BLA's) for therapeutic biologics on carrying out in vivo drug metabolism and metabolic drug-drug interaction studies. The guidance reflects the agency's current view that the metabolism of a new drug should be defined during drug development and that its interactions with other drugs should be explored as part of an adequate assessment of the safety and effectiveness of the drug.

DATES: General comments on agency guidance documents are welcome at any time.

ADDRESSES: Submit written requests for single copies of the draft guidance to the Drug Information Branch (HFD–210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or to the Office of Communication, Training, and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research (CBER), 1401 Rockville Pike,